Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCM-AGH in Moderate to Severe Atopic Dermatitis
NCT04179760Phase 2Completed
- Sponsor
- SCM Lifescience Co., Ltd.
- Start
- Mar 2020
- Primary completion
- Aug 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of SCM-AGH in atopic dermatitis (AD), sponsored by SCM Lifescience Co., Ltd.. Started Mar 2020; status: completed.
02
Drugs
SCM-AGH
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04179760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179760.